Tregs constrain CD8⁺ T cell priming required for curative intratumorally anchored anti-4-1BB immunotherapy.

ABSTRACT: Although co-stimulation of T cells with agonist antibodies targeting 4-1BB (CD137) improves antitumor immune responses in preclinical studies, clinical development has been hampered by on-target, off-tumor toxicity. Here, we report the development of a tumor-anchored ɑ4-1BB agonist (ɑ4-1BB-LAIR), which consists of an ɑ4-1BB antibody fused to the collagen binding protein LAIR. While combination treatment with an antitumor antibody (TA99) displayed only modest efficacy, simultaneous depletion of CD4⁺ T cells boosted cure rates to over 90% of mice. We elucidated two mechanisms of action for this synergy: ɑCD4 eliminated tumor draining lymph node Tregs, enhancing priming and activation of CD8⁺ T cells, and TA99 + ɑ4-1BB-LAIR supported the cytotoxic program of these newly primed CD8⁺ T cells within the tumor microenvironment. Replacement of ɑCD4 with ɑCTLA-4, a clinically approved antibody that enhances T cell priming, produced equivalent cure rates while additionally generating robust immunological memory against secondary tumor rechallenge.

SUBMITTER: Palmeri JR 

PROVIDER: S-EPMC9915483 | biostudies-literature | 2023 Feb

REPOSITORIES: biostudies-literature